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Abstract
Human embryonic stem (hES) cells activate a rapid apoptotic response after DNA damage but the
underlying mechanisms are unknown. A critical mediator of apoptosis is Bax, which is reported to
become active and translocate to the mitochondria only after apoptotic stimuli. Here we show that
undifferentiated hES cells constitutively maintain Bax in its active conformation. Surprisingly,
active Bax was maintained at the Golgi rather than at the mitochondria, thus allowing hES cells to
effectively minimize the risks associated with having pre-activated Bax. After DNA damage,
active Bax rapidly translocated to the mitochondria by a p53-dependent mechanism. Interestingly,
upon differentiation, Bax was no longer active and cells were not acutely sensitive to DNA
damage. Thus, maintenance of Bax in its active form is a unique mechanism that can prime hES
cells for rapid death, likely to prevent the propagation of mutations during the early critical stages
of embryonic development.
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Introduction
Human embryonic stem (hES) cells have the unique capability of differentiating into all cell
types, leading to the development of an entire organism (Jaenisch and Young, 2008;
Thomson et al., 1998). As the integrity of ES cells is critical for the developing embryo,
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these cells have likely evolved mechanisms that detect and respond rapidly to adverse
stimuli. Indeed, hES cells have been shown to be highly sensitive to DNA damage, but the
molecular mechanisms underlying this rapid death remain unclear (Filion et al., 2009;
Grandela et al., 2008; Momčilović et al., 2009; Qin et al., 2007).
Caspases are critical mediators of apoptosis in mammalian cells and a key protein that
controls their activation is Bax, a proapoptotic member of the Bcl-2 family (Tait and Green,
2010; Youle and Strasser, 2008). In healthy cells, Bax has been reported to be
predominantly cytosolic, present in an inactive conformation. However, apoptotic stimuli
such as DNA damage activate signaling pathways that result in the induction of BH3-only
family proteins that promote a change in Bax conformation (Brunelle and Letai, 2009;
Chipuk et al., 2010). Activated Bax then translocates to the mitochondria where it induces
cytochrome c release and apoptosome-mediated caspase activation, resulting in apoptotic
cell death (Dewson and Kluck, 2009; Taylor et al., 2008). Thus, Bax activation is a critical
event in the commitment of cells to apoptosis.
Considerable details of the mechanism by which Bcl-2 family proteins regulate Bax
activation have recently emerged. Bax can be directly activated via binding to a subset of
BH3-only proteins known as “activators” (e.g. Bim, Bid, and Puma). However, the
antiapoptotic members of the Bcl-2 family (e.g. Bcl-2, Bcl-XL) can also bind to Bax and
prevent its function. A second subset of BH3-only proteins known as “sensitizers” (e.g. Bad,
Noxa, Bmf) bind to and inactivate the antiapoptotic Bcl-2 family proteins and therefore, may
also be needed to enable efficient Bax activation (Giam et al., 2008; Shamas-Din et al.,
2011). Importantly, structural studies have shown that binding of the BH3-only activators to
Bax induces a conformational change in Bax that exposes the N-terminus and mobilizes the
C-terminus to insert into the mitochondrial outer membrane. These conformational changes
enable Bax to oligomerize and form pores in the mitochondrial membrane that trigger the
release of cytochrome c (Gavathiotis and Walensky, 2011). Adding to this complexity, Bax
activation can also be regulated in cells by cytosolic factors such as Ku70, a protein also
involved in non-homologous end joining DNA repair, that binds to inactive Bax and
prevents its activation (Cohen et al., 2004; Gomez, 2007). Apoptotic stimuli result in the
acetylation of Ku70 and the disruption of the Bax-Ku70 complex, facilitating Bax activation
(Cohen et al., 2004; Li et al., 2007; Subramanian et al., 2005).
While the main components of the apoptotic pathway have been identified, exactly how this
pathway is regulated in various primary cells remains unclear. Here, we examined the
apoptotic pathway in hES cells and report a unique mechanism engaged by hES cells that
can prime them to undergo rapid apoptosis in response to genotoxic damage.
Results
hES cells engage rapid apoptosis after DNA damage that is p53-dependent
To examine the apoptotic pathway in hES cells, we treated them with various stimuli that
induce apoptosis. We found that DNA damage activates very rapid death in H9 hES cells,
with all cells dying by 5 hours after etoposide treatment (Figures 1A, B). This death was
apoptotic as it resulted in caspase-3 activation and was completely prevented by the addition
of the pan-caspase inhibitor z-VAD-fmk (Figures 1A, B, C). hES cells were remarkably
more sensitive to etoposide than fibroblasts in a time- and dose-dependent manner (Figure
S1A). Furthermore, this sensitivity of hES cells was selective to DNA damage. While
exposure to either etoposide or doxorubicin induced rapid apoptosis, tunicamycin and taxol
treatments, which induce apoptosis by ER stress and microtubule stabilization respectively,
did not induce hES cell death within this timeframe (Figure 1D).
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hES cell death in response to DNA damage was also p53-dependent, as phosphorylated p53
(Ser15) accumulated after etoposide treatment (Figure S1B) and shRNA-mediated knock
down of p53 completely blocked hES cell death (Figure 1E, Figure S1C). p53 can induce
cell death either by localizing to the nucleus and activating proapoptotic genes such as Noxa
or Puma (Nakano and Vousden, 2001; Oda et al., 2000; Yu et al., 2001) or by a faster,
transcription independent mechanism whereby it translocates to the mitochondria and
directly interacts with members of the Bcl-2 family to promote cytochrome c release
(Chipuk et al., 2004; Mihara et al., 2003). Following DNA damage, p53 was detectable only
in the nuclei of etoposide-treated hES cells (Figure 1F). Furthermore, addition of the protein
synthesis inhibitor cycloheximide prevented the etoposide-induced death of hES cells
(Figure S1D). Thus, the rapid apoptotic death of hES cells was likely mediated by a protein
synthesis-dependent activity of p53, rather than by direct translocation to the mitochondria.
Bax is constitutively activated in hES cells
Bax and Bak are the two main proapoptotic members of the Bcl-2 family that directly
mediate mitochondrial permeabilization during apoptosis. We found etoposide-induced hES
cell death to be Bax-dependent but Bak-independent (Figures 2A, B, Figure S2A), indicating
that Bax is the key inducer of apoptosis in these hES cells. Typically, in untreated cells, Bax
is present in its inactive, monomeric conformation in the cytosol (Hsu, 1997). However,
after the induction of apoptosis, Bax undergoes a conformational change, oligomerizes, and
inserts into the outer mitochondrial membrane where it promotes the release of cytochrome
c which results in caspase activation (Antonsson, 2001; Wolter et al., 1997; Youle and
Strasser, 2008). To determine the kinetics of Bax activation in hES cells, we immunolabeled
untreated and etoposide treated hES cells using the Bax 6A7 antibody, which detects Bax
only in its active conformation (Hsu and Youle, 1997). Surprisingly, we found Bax to be in
its active state in the untreated hES cells (Figures 2C). These results were unexpected
because thus far Bax activation has been seen only in cells that are actively undergoing
apoptosis (Youle and Strasser, 2008) (Figure S2B). However, we found no evidence of cell
death in untreated hES cells that have activated Bax (Figure 2C and Figure S2C). We
additionally confirmed that the Bax 6A7 staining was specific for Bax as shRNA-mediated
knock down of Bax decreased active Bax staining in hES cells (Figure 2D). Consistent with
the observation that Bax is maintained in an active state, active Bax was immunoprecipitated
with the 6A7 antibody in untreated hES cells (Figure 2E). In contrast, in a human fibroblast
line (CCL-151), the active form of Bax could only be detected upon the induction of
apoptosis (Figure 2E). The observation that hES cells have Bax in its active conformation
provides insight into how these cells are able to rapidly induce apoptosis after DNA damage.
However, this raised the question of how hES cells are capable of maintaining Bax in its
active state without spontaneously activating apoptosis.
Constitutively activated Bax is localized to the Golgi in hES cells
In cells undergoing apoptosis active Bax localizes to the mitochondria to promote caspase
activation (Brunelle and Letai, 2009; Gross et al., 1999; Hsu, 1997; Wolter et al., 1997).
Based on our observation that hES cells are Bax 6A7 positive, we asked whether active Bax
was localized to the mitochondria of untreated hES cells. Unexpectedly, we found active
Bax to be localized not at the mitochondria but at the Golgi in the untreated hES cells
(Figure 3A and Figures S3A, B, C). Co-immunolabeling of hES cells with Bax 6A7 and
TGN46, a protein maintained at the trans-Golgi network, showed that active Bax is
specifically localized to the trans-Golgi compartment; no colocalization was seen with the
cis-Golgi marker GM130 (Figures 3A, B). Consistent with the observation that active Bax
was localized at the Golgi, treatment of hES cells with Brefeldin A, a known Golgi complex
disassembly agent (Fujiwara et al., 1988), altered Bax localization in hES cells (Figure
S3C). Importantly, in addition to our findings that the 6A7 antibody labeled Bax at the
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Golgi, we found ectopically expressed GFP-Bax to be localized to the trans-Golgi
compartment in hES cells, in contrast to the cytosolic localization that is seen in other cell
types (Figure 3C). To confirm Bax localization to the Golgi using biochemical techniques,
we also conducted subcellular fractionation of hES cells by sucrose gradient
ultracentrifugation. Our results show strong localization of Bax in the Golgi-enriched
fractions of hES cells. In contrast, no Bax was detected in the Golgi fractions in HeLa cells
(Figure 3D). To examine whether active Bax at the Golgi was also seen in other hES cell
lines, we examined the status of Bax in a panel of four hES and four non-hES cell lines.
Indeed, we found Bax to be in an active conformation and localized to the Golgi in three of
the four hES cell lines we tested (H9, H7, CHB6; see Discussion section). Importantly, no
active Bax was detected in any of the non-hES cells tested (Figure 3E). Thus, multiple
experimental approaches show that activated Bax is found at the Golgi of healthy, untreated
hES cells.
Early hES cell differentiation changes Bax status and sensitivity to DNA damage
We noticed that a subset (approximately 30–35%) of untreated hES cells did not have Bax in
its active conformation. Since the cell cycle distribution in a population of hES cells is
reported to be mostly in S phase (65%), followed by G0-G1 (20%) and G2-M (15%)
(Becker et al., 2006), we investigated whether the presence of active Bax in hES cells was
correlated with the cell cycle state. We labeled untreated hES cells with Bax 6A7, EdU (S
phase marker), and DAPI (for DNA) and conducted FACS analysis to identify the
population of cells with active Bax. Our results showed that Bax 6A7 positive cells were
almost exclusively (greater than 95%) in the S phase of the cell cycle (Figure 4A).
As hES cells have the potential to be differentiated into all cell lineages, we examined
whether the constitutively active status of Bax seen in undifferentiated hES cells changes
with differentiation. Differentiation of hES cells can be achieved by removing cells from
feeder layers or matrixes and allowing them to grow in suspension on a non-adherent
surface (Odorico et al., 2001). hES cells begin to differentiate under these conditions and
form aggregates called embryoid bodies which can be dissociated for analysis. Interestingly,
Bax was found in its active conformation only in undifferentiated hES cells; Bax was no
longer present in its active state after just two days of differentiation (Figure 4B and Figure
S4). Consistent with the idea that the presence of active Bax in undifferentiated hES cells
primes them for rapid apoptosis, the two-day differentiated hES cells that do not have active
Bax were also no longer acutely sensitive to DNA damage (Figures 4C, D). These results
illustrate how the apoptotic machinery undergoes dynamic changes to set apoptotic
thresholds even at the earliest stages of hES cell differentiation.
p53 is required for translocation of active Bax to mitochondria after DNA damage
Confocal analysis using triple labeling with Bax 6A7, TGN46 (Golgi), and Tom20
(mitochondria) antibodies confirmed active Bax to be localized at the Golgi in untreated hES
cells (Figure 5A). Next, we examined whether active Bax changes localization after DNA
damage. As early as 3 hours after etoposide treatment Bax 6A7 co-localized with the
mitochondrial marker Tom20, indicating that active Bax translocates from the Golgi to the
mitochondria in hES cells undergoing apoptosis (Figure 5B and Figure S5). Bax was
localized to distinct focal points at the mitochondria during apoptosis, as previously
described (Karbowski et al., 2002; Nechushtan et al., 2001). Bax translocation to the
mitochondria was also confirmed with another Bax antibody (2D2) that showed a similar
pattern of Bax localization to mitochondrial foci upon etoposide treatment in hES cells
(Figure 5C). As our results show that apoptosis after DNA damage in hES cells was p53-
dependent, we investigated whether p53 was necessary for the translocation of active Bax
from the Golgi to mitochondria. Indeed, we found active Bax to be maintained at the Golgi
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after etoposide treatment in the p53-knock down hES cells, indicating that p53 was required
for the Golgi-to-mitochondria translocation of active Bax after DNA damage (Figures 5D,
E).
Inactivation of Bcl-2 and Bcl-XL does not alter Golgi localization of Bax in hES cells
The antiapoptotic members of the Bcl-2 family such as Bcl-2 and Bcl-XL have been shown
to inhibit Bax-induced mitochondrial permeabilization (Youle and Strasser, 2008). We
examined whether these proteins were important for maintaining Bax at the Golgi and
restricting its translocation to the mitochondria in untreated hES cells. Addition of
ABT-737, an inhibitor of Bcl-2 and Bcl-XL (Oltersdorf et al., 2005), did not change
localization of active Bax at the Golgi (Figure 6A). Consistent with this observation, we did
not detect either Bcl-2 or Bcl-XL at the Golgi in hES cells (Figure 6B). Treatment with
ABT-737 alone also did not induce hES cells to undergo apoptosis. However, ABT-737
addition increased the rate of etoposide-induced hES cell death, with nearly 60% of cells
dying by 2 hours after etoposide treatment (Figure 6C). These results suggest that
inactivation of Bcl-2 and Bcl-XL alone is not sufficient to trigger Bax translocation to the
mitochondria in the absence of an apoptotic stimuli in hES cells.
Ku70 is constitutively acetylated and does not interact with Bax in untreated hES cells
Previous studies have found Bax to be maintained in an inactive form in a complex with
Ku70 (Cohen et al., 2004; Subramanian et al., 2005). A peptide containing the Ku70 binding
domain (Bax inhibitory peptide, BIP) potently binds inactive Bax and prevents its activation
(Yoshida et al., 2004). Because Ku70 cannot bind active Bax, BIP is unable to block
apoptosis once Bax is activated. We investigated the ability of BIP to block apoptosis in hES
cells following DNA damage as an alternative method of confirming that Bax is pre-
activated in hES cells. As anticipated, BIP could effectively inhibit apoptosis in HeLa cells
but not in hES cells where Bax is already in its active conformation (Figures 7A, B).
In response to DNA damage, Ku70 becomes acetylated by histone acetyl-transferases,
resulting in the release of Bax and the subsequent translocation of Bax to mitochondria
(Cohen et al., 2004; Subramanian et al., 2005). Because we found that Bax was in its active
conformation in untreated hES cells, we examined the acetylation status of Ku70 in these
cells. Our immunoprecipitation results show that Ku70 is constitutively acetylated in the
untreated hES cells (Figure 7C). In contrast, Ku70 was acetylated only after DNA damage in
HEK293 and HeLa cells (Figure 7C, data not shown). Consistent with the model that
acetylated Ku70 can no longer bind Bax, we found no interaction between Ku70 and Bax in
untreated hES cells (Figure 7D). These results in hES cells are distinct from those in
HEK293 and HeLa cells, where Bax co-immunoprecipitated with Ku70. The interaction
between Bax and Ku70 was disrupted only after the acetylation of Ku70 as a consequence of
DNA damage in these cells (Figures 7C, D, data not shown). These results identify an
interesting feature of hES cells in which Ku70 is constitutively acetylated in the absence of
DNA damage, and therefore incapable of sequestering Bax.
Discussion
Here we describe the striking observation that healthy undifferentiated hES cells maintain
Bax in its pre-activated state at the Golgi. This is in contrast to other cell types in which Bax
is typically present in an inactive form in the cytosol. Importantly, as early as 3 hours after
DNA damage, active Bax translocates from the Golgi to the mitochondria in a p53-
dependent manner. We propose that by sequestering active Bax at the Golgi, hES cells are
able to effectively minimize the risks associated with having pre-activated Bax yet maintain
their ability to respond rapidly to genotoxic insults.
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Detailed biochemical and structural studies on the mechanism of how Bax is activated have
emerged in recent years. However, exactly how Bax activation is regulated in various
primary cells remains largely unexplored. This is particularly important as different cell
types may modify their apoptotic threshold in order to function in, and adapt to, different
physiological conditions. Typically, Bax is activated by the BH3-only proteins in a rapid
sequence of events. The direct binding of the activator BH3-only proteins to Bax induces a
conformation change in the N-terminus (recognized by the 6A7 antibody) which is followed
immediately by the mobilization of the C-terminal transmembrane domain and the insertion
of Bax on the mitochondrial outer membrane (Walensky and Gavathiotis, 2011). Our results
show that these steps of Bax activation are uncoupled in hES cells with the 6A7 positive
form of Bax stabilized without mitochondrial translocation. Whether the maintenance of
active Bax is dependent on some BH3-only proteins in hES cells is not known. The full
repertoire of BH3-only proteins expressed in hES cells is unknown and the simultaneous
knock down of multiple members may be needed to discern their importance in inducing
Bax activation. Recently, a constitutively active isoform of Bax (Baxβ) was detected in
various cell lines. However, in contrast to our results in hES cells, the Baxβ isoform was
found at the mitochondria and only detected in the presence of proteasome inhibitors in the
cell lines analyzed (Fu et al., 2009).
A recent study found Bax to shuttle between the cytosol and mitochondria in healthy cells
and that Bcl-XL is important for the retrotranslocation of Bax from the mitochondria to
cytosol (Edlich et al., 2011). We specifically examined whether Bcl-2 and Bcl-XL were
important for maintaining active Bax at the Golgi and preventing its spontaneous
translocation to mitochondria. While both Bcl-2 and Bcl-XL are known to promote hES cell
survival (Ardehali et al., 2011; Bai et al., 2012), our results show that inhibition of these
proteins alone did not change the status of active Bax or trigger apoptosis in hES cells. The
association of Bax with Ku70 has been reported as one mechanism by which Bax is
maintained in an inactive conformation (Cohen et al., 2004; Subramanian et al., 2005).
Importantly, we found that Ku70 is constitutively acetylated and therefore unable to bind
Bax in hES cells. These results contrast the findings in other cell types where the Ku70-Bax
complex is disrupted only when Ku70 is acetylated by histone acetyltransferases (e.g. p300/
CBP, PCAF) in response to apoptotic stimuli (Cohen et al., 2004; Subramanian et al., 2005).
The observation that Ku70 is constitutively acetylated and unable to bind to Bax provides
insight into how Bax is available for activation in hES cells.
Our results also highlight the fact that the apoptotic machinery undergoes dynamic changes
even at early stages of differentiation. While undifferentiated hES cells have constitutively
active Bax and undergo rapid apoptosis in response to DNA damage, just 2 days of
differentiation induced significant changes such that Bax was no longer active, and the cells
were no longer highly sensitive to DNA damage. This could be manifested with even greater
complexity in vivo as cells during early embryogenesis undergo rapid proliferation and
differentiation. While most of our studies were done in the H9 hES cell line, we also
examined the status of Bax in a panel of other hES cells. Like the H9 hES cells, the H7 and
CHB6 hES cells also exhibited 6A7 positive Bax staining at the Golgi (Figure 3E).
However, the staining intensity was weaker in the H7 and CHB6 hES cells (requiring
confocal imaging) as compared to the H9 hES cells, and negative in the H1 hES cells. Thus,
we anticipate that there may be differences in the status of the apoptosis machinery between
various hES cell lines potentially as a consequence of their derivation from the inner cell
mass at different time points during blastocyst outgrowth.
Recent evidence demonstrates that sustained treatment of ES cells with DNA damaging
agents can predispose ES cells to karyotypic abnormalities (Bueno et al., 2009; Stambrook
and Tichy, 2010). Therefore, the ability to maintain genomic integrity in ES cells is of
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critical importance to prevent propagation of mutations to the developing embryo and
reduce the risk of carcinogenesis. Because hES cells are critical for embryogenesis, yet need
to be sensitive to genomic perturbations, their ability to engage a rapid death after DNA
damage is likely a key evolutionary adaptation for optimal organismal development.
Materials and Methods
Cell Culture
Human embryonic stem cell lines H9 (WA09) and H7 (WA07), H1 (WA01) were obtained
from WiCell Research Institute (Wisconsin). CHB6 hES cells were obtained from Dr.
George Daley (Children’s Hospital, Boston). Cells were seeded as undifferentiated colonies
on plates coated with fibronectin (Sigma), maintained at 37°C and 5% CO2, and fed mouse
embryo fibroblasts (MEF) conditioned human ES culture medium plus bFGF daily. For
CHB6 hES cells and certain experiments that required larger number of cells, hES cells were
seeded on matrigel and fed daily with mTeSR media (Stem Cell Technologies).
Differentiation of hES cells was induced by plating 4-day-old colonies onto non-adherent
plates without fibronectin and fed non-conditioned hES cell media daily. All experiments
with hES cells were conducted with the H9 cell line. As indicated, the experiment in Figure
S3C was conducted in the H7 cell line.
The human lung fibroblast cells (CCL-151), HEK293T cells, and HeLa cells were received
from ATCC and maintained and cultured as recommended by the supplier in modified
Ham’s F12 (F-12K) medium supplemented with 15% FBS (CCL-151) and Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10% FBS and 1% L-glutamine
(HEK293 T cells). Human dermal fibroblasts (HDF UNCH1) were received from the Tissue
Culture Facility at UNC and maintained in DMEM/F12 + 5% FBS.
Cell Treatments
All treatments were performed on day 4–5 for hES cells or at 80% confluency for
fibroblasts. Etoposide (Sigma) was added at a final concentration of 20 μM to hES cells and
fibroblasts unless otherwise stated. Staurosporine (Sigma) was added to a final concentration
of 200 nM. The pan-caspase inhibitors Z-VAD-FMK (MP Biomedicals) and Q-VD-OPH
(SM Biochemicals) were added to the cells at a concentration of 50 μM (Z-VAD) and 25
μM (QVD-OPH). Cycloheximide (Sigma) was added at a final concentration of 1 μg/ml for
5 hrs. The cell impermeable dyes propidium iodide and sytox green (Molecular Probes)
were added to hES cells at a final concentration of 1 μg/ml (propidium iodide) and 10 nM
(sytox green) and incubated at 37ºC in the dark for 20 min. Membrane permeable peptides,
negative control and Bax inhibiting peptide (BIP) were purchased from Calbiochem. The
stock solutions were prepared in DMSO and the peptides were added directly into medium
(final concentration: 200 μM) at 37 °C 1hr before apoptosis treatments. ABT-737 was
purchased from Selleck Chemicals LLC (Houston TX, USA) and stock solutions were
prepared in DMSO. hES cells were treated with etoposide (20 μM) for 5 hours and HeLa
cells for 16–24 hours. Cell survival was assessed at multiple time points by morphology (by
counting the total number of cells attached with intact morphology in a defined area at each
timepoint). Wherever indicated, cell death was also quantitated by counting apoptotic nuclei
(condensed or fragmented) stained with Hoechst Staining or with propidium iodide dye
exclusion. Golgi was disrupted using Brefeldin A (5 μg/ml; Sigma) for 15 minutes at 37ºC.
All experiments were repeated at least 3 times and error bars indicate standard deviation.
Lentiviral Transduction
To generate lentiviral-mediated knock down lines of hES cells, day 3 hES cell colonies were
transduced with p53, Bax or Bak lenti-shRNAs (Open Biosystems) for 10 hours. After 10
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hours, the cells were allowed to recover for 12–14 hours in fresh conditioned medium.
Selection with puromycin (10 μg/ml; Sigma) was started 24 hours after the initiation of the
transduction and was continued for 4 days, with replacement of the conditioned medium and
puromycin every day. Transduction efficiency was validated by Western blotting on healthy,
recovered hES cell colonies.
Transfection, Immunofluorescence, and Immunoprecipitation
To visualize GFP-tagged Bax, 3-day colonies of hES cells were transfected with 2 μg of
hBaxC3-EGFP (Addgene) with FuGENE HD transfection reagent (Roche). EdU labeling
and detection was performed using a flow cytometry kit according to manufacturer’s
instructions (Click-iT EdU Alexa Fluor 594, Invitrogen, Carlsbad, CA). DAPI (2 μg/ml;
Sigma, St. Louis, MO) was used to measure the DNA content. Samples were subjected to
FACS analysis as measured on a Dako CyAN ADP instrument. For immunofluorescence,
cells were fixed with 4% paraformaldehyde for 30 min at 4ºC and permeabilized in 0.3%
Triton X-100 (or 0.04% Saponin in Supplementary Fig. S3B) for 1 hr at room temperature.
After blocking, cells were then treated with primary and secondary antibodies using standard
methods. Immunoprecipitation experiments were performed in order to detect the active
form of Bax (using CHAPS buffer), the acetylation status of Ku70 (using Triton X-100
buffer), and the interaction status between Bax and Ku70 (using CHAPS buffer).
Subcellular Fractionation
To separate the Golgi from the mitochondrial fraction we performed subcellular
fractionation as previously described (Jesch and Linstedt, 1998). Briefly, hES cells were
collected by centrifugation (2,000 rpm) for 5 min, washed once in PBS (containing 1 mM
EDTA), washed once in sucrose buffer (250 mM sucrose, 10 mM triethylamine pH 7.4, 1
mM EDTA, with protease inhibitors), homogenized by 20 passages through a 25-gauge
needle in 0.5 ml homogenization buffer (50 mM NaCl, 10 mM triethylamine, pH 7.4, 1 mM
EDTA, with protease inhibitors), and centrifuged at 1,000 × g for 2 min. The postnuclear
supernatant was adjusted to 1.6 M sucrose (1.1 ml), layered on 2 M sucrose (0.5 ml),
covered with three sucrose layers (1.1 ml each: 1.4 M, 1.2 M, 0.8 M), and centrifuged at
105,000 × g for 105 min in a MLS-50 rotor (Beckman), and 0.4-ml fractions were collected
from the top. All steps were carried out at 0–4°C. Immunoblotting was used to assay each
fraction for the presence of Bax (N20), Golgi (TGN46) and mitochondria (VDAC).
Image acquisition
Images were acquired using a Hamamatsu ORCA-ER digital B/W CCD camera mounted on
a Leica inverted fluorescence microscope (DMIRE 2). The software used for image
acquisition was Metamorph version 5.0 (Universal Imaging Corporation). Confocal images
were taken on an Olympus FV1000 confocal microscope.
Additional detailed description of the methods is included in the Supplementary
Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• hES cells have constitutively active Bax and are highly sensitive to DNA
damage
• Constitutively active Bax is localized to the Golgi in hES cells
• DNA damage triggers a p53 dependent translocation of Bax from Golgi to
mitochondria
• hES cell differentiation changes status of active Bax and sensitivity to DNA
damage
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hES cells engage rapid apoptosis after DNA damage. H9 hES cells were either left untreated
or treated with 20 μM etoposide in the absence or presence of the caspase inhibitor z-
VAD.fmk (50 μM). Shown are phase contrast images after 5 hrs of treatment (A) and
quantification of cell survival. Error bars represent ±SD for triplicate experiments. (B). (C)
Untreated and 3 hrs etoposide treated (20 μM) hES cells were fixed and stained with anti-
cleaved caspase-3 antibody and Hoechst 33258 (nuclei). Immunofluorescence images show
that the untreated hES cells do not have active caspase-3 but it becomes activated as early as
3 hrs after the initiation of the treatment. (D) Quantification of cell death (using nuclear
fragmentation) of hES cells treated with Tunicamycin (5 μM), Taxol (1 μM), Etoposide (20
μM), or Doxorubicin (1 μM) as indicated in the figure. Error bars represent ±SD for
triplicate experiments. (E) Upper panel: wildtype (wt) and p53 knock-down (shp53) hES
cells were treated with 20 μM etoposide (Etop) and cell survival was quantified at various
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times after etoposide treatment. Lower panel: wildtype (wt) and p53-knock-down (shp53)
hES cells were treated with 20 μM etoposide for 3 hrs and immunoblotted with an anti-p53
antibody. Wildtype hES cells were also treated with zVAD.fmk to prevent any cell death.
Error bars represent ±SD for triplicate experiments. Western blot shows the efficient
downregulation of p53. (F) Wildtype hES cells were treated with 20 μM etoposide for 2
hours and immunolabeled for p53, cyt c and the nuclear stain Hoechst 33258. The
immunofluorescence images show the upregulation and nuclear localization of p53 after
etoposide treatment.
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Bax is constitutively active in hES cells. (A) Wildtype (wt) and Bax knock-down (shBax)
hES cells were treated with 20 μM etoposide for 5 hrs and immunoblotted for total Bax.
Western blot shows efficient knock down in Bax levels in shBax expressing cells. (B)
Quantification of cell survival in wt and Bax knock-down hES cells at various times after
etoposide (20 μM) treatment. Error bars represent ±SD for triplicate experiments. (C) hES
cells were immunostained with anti-Bax 6A7 and anti-cleaved caspase-3 antibodies. Images
show active Bax but no caspase-3 activation in untreated hES cells. (D) Wildtype (wt) or
Bax knockdown (shBax) hES cells were immunostained for active Bax with the 6A7
antibodies. Representative image shows no 6A7 positive staining in Bax-deficient hES cells
demonstrating that the 6A7 staining is Bax-dependent. (E) Immunocomplexes were
precipitated from hES and CCL-151 (human lung fibroblast cell line; untreated or treated
with 200 nM staurosporine) extracts (prepared in CHAPS buffer) with the anti-Bax 6A7
antibody and immunoblotted with a total Bax antibody (N20). The input lane was loaded as
1/10 dilution of the pre-IP extract, and IgG served as a negative control.
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Constitutively active Bax is localized to the Golgi in hES cells. (A) Untreated hES cells
were immunostained with anti-Bax 6A7 and anti-TGN46 antibodies. Hoechst 33258 was
used to label the nuclei. Immunofluorescence images show the localization of active Bax at
the Golgi (arrows). (B) Active Bax is localized at the trans-Golgi (anti-TGN46 antibody)
and not at the cis-Golgi network (anti-GM130 antibody). (C) Upper panels: Ectopically
expressed GFP-Bax shows a distinct subcellular localization in hES cells in contrast to the
cytoplasmic localization seen in HeLa cells. Lower panels: GFP-Bax immunofluorescence
(GFP antibody) shows the localization of Bax to the Golgi (TGN46) in hES cells. (D)
Subcellular fractionation of Golgi and mitochondria (Mito) in hES and HeLa cells.
Representative Western blots demonstrate that Bax (N20 antibody) can be detected in the
Golgi of hES but not of HeLa cells. TGN46 and VDAC were used as markers of Golgi and
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mitochondrial, respectively. (E) A panel of hES cells (H9, H7, CHB6, H1) and human non-
ES cells (HeLa, U87-MG, IMR-90, HDF) were probed for the status of active Bax by
immunostaining with 6A7 and TGN46 (for Golgi) antibodies. Images show that active Bax
localized to the Golgi was seen in the H9, H7 and CHB6 hES cells.
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Active Bax is present predominantly in hES cells in the S phase ; Bax is no longer active in
hES cells after differentiation. (A) Left panel: Untreated hES cells were stained with EdU,
anti-Bax 6A7 antibody and DAPI and subjected to FACS analysis as described in the
Materials and Methods. Analysis showed that Bax 6A7 positivity was seen almost
exclusively (greater than 95%) in cells going through the S phase of the cell cycle (~60% of
the total cells are in S phase). Right panel: Representative fluorescent images show that cells
that are actively replicating (EdU positive; white arrows) have Bax in its active state (6A7
positive), whereas cells that are not in the S phase (EdU negative; yellow arrowhead) do not
have active Bax (6A7 negative). Error bars represent ±SD for triplicate experiments. (B)
hES cells after one and two days of differentiation were immunostained with anti-Bax 6A7
and anti-TGN46 antibodies. Immunofluorescence images show that 2-day differentiated hES
cells are no longer positive for Bax 6A7. (C) Phase contrast images show that embryoid
bodies (2 days of differentiation) are no longer sensitive to rapid apoptosis induced by
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etoposide. (D) Quantification of cell death by nuclear morphology after treatment with 20
μM etoposide. Error bars represent ±SD for triplicate experiments.
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p53 is required for Bax translocation to mitochondria after DNA damage. (A) Triple labeled
confocal images of untreated hES cells demonstrate active Bax (6A7) colocalizing to the
Golgi (TGN46) but not the mitochondria (Tom20). (B) hES cells were either left untreated
or treated with etoposide for 5 hours (in the presence of caspase inhibitor 25 μM QVD-
OPH). Immunostaining with anti-Bax 6A7 and anti-TGN46 antibodies (and Hoechst 33258
to label nuclei) shows no colocalization of active Bax with Golgi after etoposide treatment.
Bottom panels show distinct sites of Bax 6A7 co-localization with mitochondria (anti-
Tom20 antibody) after etoposide treatment. (C) hES cells were left untreated or treated with
etoposide (20 μM) for 5 hours (in the presence of caspase inhibitor 25 μM QVD-OPH).
Immunostaining with anti-Bax 2D2 and anti-Tom20 antibodies shows translocation of Bax
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to the mitochondria after etoposide treatment. (D) p53 knock-down (shp53) hES cells were
either left untreated or were treated with etoposide for 5 hours and immunostained with anti-
Bax 6A7 and anti-TGN46 antibodies. Immunofluorescence images show that Bax 6A7
remains colocalized with TGN46 at the Golgi, even after DNA damage. (E) Quantification
of results in (D), indicating the number of wild-type (wt) and p53 knock-down (shp53) hES
cells with active Bax at Golgi before and after etoposide treatment. Error bars represent ±SD
for triplicate experiments.
Dumitru et al. Page 21














Inactivation of Bcl-2 and Bcl-XL does not change Bax status at the Golgi in hES cells (A)
hES cells were treated with 5 μM ABT-737 for 18 hrs and immunostained with anti- Bax
6A7 and anti-TGN46 antibodies. Immunofluorescence images show that ABT-737 treatment
did not affect localization of active Bax to the Golgi. (B) hES cells were immunostained
with anti-Bcl-XL or anti-Bcl-2 and anti-TGN46 antibodies. Immunostaining shows no
localization of Bcl-2 and Bcl-XL to Golgi. (C) Quantification of survival (with nuclear
morphology) in hES cells treated with ABT-737 (5 μM) or etoposide alone (20 μM) or a
combination of ABT-737 and etoposide. hES cells treated with ABT737 alone did not die
but cells treated with etoposide in combination with ABT-737 died faster than cells treated
with etoposide alone. Error bars represent ±SD for triplicate experiments.
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Ku70 is constitutively acetylated and does not interact with Bax in untreated hES cells.
(A)hES and HeLa cells were either left untreated or treated with etoposide either in the
presence of Bax Inhibiting Peptide (200 μM BIP) or a negative control peptide at the same
concentration. Results show that while BIP inhibited cell death in HeLa cells, it failed to do
so in hES cells. (B) Quantification of cell death (propidium iodide staining) after 5 hrs (hES
cells) or 16 hours (HeLa cells) of etoposide treatment (20 μM). Error bars represent ±SD for
triplicate experiments. (C) Immunocomplexes were precipitated from untreated hES and
untreated or etoposide treated HEK293T cells with the anti-pan acetylated lysine (AcK)
antibody and immunoblotted with an anti-Ku70 antibody. For untreated hES cells, a reverse
IP with anti-Ku70 antibodies and immunoblot for acetylated lysine are also shown. The
input lane was loaded as 1/10 dilution of the pre-IP extract, and IgG served as a negative
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control. (D) Immunocomplexes were precipitated from untreated hES and untreated or
etoposide treated HEK293T cells with the anti-Ku70 antibody and immunoblotted with an
anti-Bax (N20) antibody. For untreated hES cells, a reverse IP with anti-Bax antibodies and
immunoblot for Ku70 are also shown. The input lane was loaded as 1/10 dilution of the pre-
IP extract, and IgG served as a negative control. (E) Model showing the unique mechanisms
engaged by hES cells where Bax is present in its constitutively active form at the Golgi, thus
priming these cells for rapid apoptosis after DNA damage.
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